Mazdutide

A dual GLP-1/glucagon receptor agonist researched as both a fat-loss and maintenance-transition compound.

Typical bottle: 10 mg

Research note: Human research continues to define optimal dosing, long-term effects, and the appropriate role of Mazdutide across different metabolic protocols.

What It Is

Mazdutide is a long-acting dual receptor agonist targeting both the GLP-1 receptor and the glucagon receptor (GCGR). The GLP-1 component is associated with appetite control, increased satiety, and glucose regulation, while glucagon signaling is associated with energy expenditure and fat utilization.

This combination approaches body composition from two directions at once — reducing energy intake while supporting energy expenditure — and is of particular interest as a transition or maintenance compound following a more aggressive fat-loss phase, where the goal shifts from maximum appetite suppression toward maintaining results.

Who May Benefit

Fat loss and body-composition research
Appetite-regulation research
Blood-sugar regulation research
Weight-maintenance strategy research
Transitioning off a more aggressive fat-loss protocol

What to Expect

Initial phases generally involve reduced hunger and improved appetite control as the GLP-1 pathway activates, with glucagon receptor activity contributing to energy expenditure and fat utilization.

Mazdutide may be particularly useful during a transition from an aggressive fat-loss protocol into maintenance, where the objective is control rather than maximum appetite suppression. GI effects may occur, particularly during dose increases.

What to Pair It With

MOTS-C

Mitochondrial function and metabolic signaling complement Mazdutide’s dual-pathway mechanism.

AOD-9604

Fat metabolism and lipolysis research complements a body-composition-focused protocol.

Tesamorelin

Body-composition and metabolic-health research complements a maintenance-phase protocol.

Reconstitution

Vial

10 mg

Diluent

Follow selected research reconstitution volume

Note

Use a peptide calculator for exact unit dosing

Depends on reconstitution volume selected

Suggested Research Dosing Strategy

Starting Dose

1 mg

1–2× per week for approximately 3–4 weeks while evaluating sensitivity.

Standard Range

2–4 mg per week

May be divided into 1–2 administrations.

Higher Range

4–6 mg per week

Reserved for experienced research protocols.

Start low, increase gradually, and consider adjustments only every 1–2 weeks when additional effect is needed. The objective described in source material is control rather than maximum appetite suppression.

Administration Notes

Subcutaneous administration, with gradual titration to improve tolerability.

Nutrition and resistance training remain important components of any body-composition protocol built around this compound.

Monitor appetite suppression and GI tolerance closely when adjusting the dose.

Research Considerations

The combination of GLP-1 (appetite, satiety, glucose regulation) and glucagon (energy expenditure, fat utilization) signaling gives Mazdutide a different metabolic profile than GLP-1-only compounds.

A practical research progression discussed in source material: fat loss → stabilization → maintenance → transition off — positioning Mazdutide specifically for the middle-to-late phases of that sequence rather than as a maximum-intensity starting compound.

Have a specific question about Mazdutide? Chat with Pulse, Signal IQ’s free AI research assistant — ask about mechanisms, stacking, or how it compares to other compounds.

For research purposes only. Not approved for human use. This information is provided for educational and research purposes and is not medical advice. Signal IQ does not sell peptides.

All Peptides by Goal